A mouthwash medicine for the reduction or prevention of mouth ulceration caused by radiotherapy for head and neck cancer
| ISRCTN | ISRCTN87831050 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN87831050 |
| EudraCT/CTIS number | 2022-002409-99 |
| IRAS number | 1004528 |
| Secondary identifying numbers | NG11-2 P1b, IRAS 1004528, CPMS 54459 |
- Submission date
- 25/10/2022
- Registration date
- 13/02/2023
- Last edited
- 11/03/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Oral Health
Plain English summary of protocol
Background and study aims
This study is looking at a new medication called NG11-2 to see if it can reduce a side effect called severe Radiation-induced Oral Mucositis (RIOM) that can happen to people getting radiation treatment for head and neck cancer. Severe RIOM can make patients very sick and make it hard for them to finish their cancer treatment. Right now, there are no approved drugs that can prevent or treat severe RIOM. This study will test different doses of NG11-2 to find the best one, and then more patients will take that dose to see if it works. This study is being done at multiple hospitals.
Who can participate?
Patients aged 18 years or older, with head and neck cancer.
What does the study involve?
Daily treatment with NG11-2 will occur prior to radiotherapy for 5 days/week for up to 7 weeks. Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will be instructed to
a) rinse their mouth twice with room temperature water in the 5 minutes prior to NG11-2 treatment then
b) rinse their mouth with 12.5ml of NG11-2 for between 90 & 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then
c) expectorate the solution
Treatment will continue for up to 7 weeks with a 6-week follow-up period.
What are the possible benefits and risks of participating?
Benefits:
Possibly prevention/ reduction in severe Radiation-induced Oral Mucositis during the patient's radiotherapy treatment
Risks:
The study will fit in with the usual treatment and the only additional things that patients will have to do are: give a small number of extra blood samples, have some patches put on their chest for an electrocardiogram (ECG), and fill out a short questionnaire a few times. Patients will also have to rinse their mouths with the NG11-2 solution before each radiation treatment. The study drug is made with adrenaline, which is a well-understood drug, but it may cause some mild side effects like irritation in the mouth or a temporary change in heart rate. The study team will closely monitor patients for any side effects and will stop treatment if needed.
Although the scientific rationale and earlier laboratory studies suggest that NG11-2 treatment is unlikely to have a negative impact on your tumour treatment, we cannot yet exclude the risk of a negative impact on your anticancer therapy when treated with NG11-2.
Where is the study run from?
VasoDynamics Ltd (UK)
When is the study starting and how long is it expected to run for?
October 2022 to August 2024
Who is funding the study?
VasoDynamics Ltd (UK)
Who is the main contact?
Dr Mary Lei, Mary.Lei@gstt.nhs.uk
Contact information
Public
Stevenage Biocatalyst Centre
Gunnels Wood Rd
Stevenage
SG1 2FX
United Kingdom
| Phone | +44 1438 300880 |
|---|---|
| gary.bower@vasodynamics.co.uk |
Principal Investigator
Dept of Clinical Oncology
14th floor, Tower Wing
Guy’s Hospital
Great Maze Pond
London
SE1 9RT
United Kingdom
| Phone | +44 20 71884219 |
|---|---|
| Mary.Lei@gstt.nhs.uk |
Scientific
Stevenage Biocatalyst Centre
Gunnels Wood Rd
Stevenage
SG1 2FX
United Kingdom
| fiona.li@vasodynamics.co.uk |
Study information
| Study design | Interventional non-randomized dose escalation study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | ISRCTN87831050_PIS_V1.2.pdf |
| Scientific title | A phase-1b dose escalation study to assess the effect of NG11-2 on radiation induced oral mucositis in patients with head & neck cancer |
| Study acronym | NG11-2-P1b |
| Study objectives | The main objective of the trial is to see if the use of vasoconstrictors (such as Adrenaline), when administered as a mouthwash in head and neck cancer patients prior to their radiotherapy, is tolerable and can reduce or prevent the development of severe radiation induced oral mucositis. More specifically, the trial aims to identify an appropriate dose of NG11-2 IMP based on safety and activity/preliminary efficacy for subsequent assessment in follow-up clinical trials. Although the primary objective of the trial is to evaluate the safety & tolerability of NG11-2 mouthwash, the secondary objective is to obtain preliminary data on the activity/efficacy of NG11-2 mouthwash in the reduction of severe RIOM. |
| Ethics approval(s) | Approved 23/01/2023, (West Midlands - Coventry & Warwickshire Research Ethics Committee, The Old Chapel, Royal Standard Place , Nottingham, NG1 6FS, UK; +44 207 104 8184; coventryandwarwick.rec@hra.nhs.uk), ref: 22/WM/0262 |
| Health condition(s) or problem(s) studied | Reduction of radiation-induced oral mucositis in head & neck cancer patients undergoing radiotherapy with or without concomitant chemotherapy |
| Intervention | This is an unblinded, single-arm study. Patients will undergo daily treatment with NG11-2 immediately prior to radiotherapy for 5 days/week (Mon-Fri) for up to 7 weeks. The dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse. Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will be instructed to a) rinse their mouth twice with room temperature water in the 5 minutes prior to NG11-2 treatment then b) rinse their mouth with 12.5 ml of NG11-2 for between 90 & 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then c) expectorate the solution. Treatment will continue for up to 7 weeks with a 6-week follow-up period. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | NG11-2 Mouthwash, 0.92 – 5.50 mg/mL [L-adrenaline base] |
| Primary outcome measure | Occurence of Dose Limiting Toxicities (DLT) & Serious Adverse Events (SAE). Serious Adverse Events will be evaluated throughout the study from time of patient consent until 42 days after last IMP dose. Dose limiting toxicities will be evaluated from time of first dose until 42 days after last IMP dose. Additionally all available safety data (AEs, SAEs and DLTs) will be reviewed and evaluated by a Safety Committee (Sponsor CMO, Study Medical Monitor & Chief Investigator) before each dose escalation. |
| Secondary outcome measures | 1. Duration of severe RIOM (WHO, RTOG and NCI-CTCAE v5 Gr 3 or above) evaluated by Oral Mucositis assessments at screening and twice weekly in each week of study treatment in weeks 1-7, and then at 7, 14, 28 and 42 days post end of Radiotherapy, in the follow-up period. 2. Incidence & Time to onset of severe RIOM (WHO, RTOG and NCI-CTCAE v5 Gr 3 or above) 3. Patient Reported Outcome Measure - Oral Mucositis (PROM-OM) evaluated at the same timepoints as the clinical Oral Mucositis assessments, namely screening and twice weekly in each week of study treatment in weeks 1-7, and then at 7, 14, 28 and 42 days post end of Radiotherapy, in the follow-up period. |
| Overall study start date | 21/10/2022 |
| Completion date | 20/08/2024 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Up to 32 maximum - estimated 20-24 |
| Total final enrolment | 15 |
| Key inclusion criteria | 1. Male or female head and neck cancer patients scheduled for radiotherapy, aged 18 or over on day of signing informed consent; 2. Histologically confirmed head and neck cancer with or without previous resective surgery, having not been previously treated with radiation therapy 3. Scheduled to receive a mean radiation dose of no less than 30 Gy on either (a) Extended Oral Cavity, or (b) Buccal Mucosa, or (c) Lips, according to CT-based delineation of Organ-At-Risk (OAR) Guideline, with or without concurrent chemotherapy (Section 13.8 for guidance); 4. Rendered dentally fit for radiotherapy; 5. Have a Performance Status >60 on the Karnofsy scale 6. No evidence of active systemic infections at the time of screening; 7. No oral fungal infection by visual examination or swab test; 8. Body Mass Index >=18.5 kg/m² 9. Normalcy of diet evaluated with the Performance Status Scale for Head and Neck cancer patients (PSSHN) >=30; 10. Ability to retain and swill liquid inside the oral cavity for at least 90 seconds; 11. Female patients of childbearing potential must have a negative urine or serum pregnancy test during the 2 week Screening period 12. Provide written informed consent for the trial. 13. Consent to utilize medically acceptable methods of contraception throughout the study period if of child-bearing potential; 14. Be able to comply with protocol procedures (such as Oral Mucositis assessment and swish/spit) and study schedule |
| Key exclusion criteria | 1. Tumour of the larynx 2. Mentally or legally incapacitated, in the opinion of the PI, which could interfere with the ability of the patient to understand or adhere to the requirements of the study; 3. Open or unhealed non-cancerous wounds or ulcers in the oral cavity; 4. WHO Oral Mucositis grade of 2 or more 5. Uncontrolled Hypertension, defined as blood pressure in adults >150/100mm Hg at screening; 6. A known clinically significant abnormal ECG, such as arrhythmia and active ischemia,within 6 months prior to treatment; 7. Xerostomia or hyposalivation; 8. Known allergy or intolerance to sympathomimetic drugs (e.g., pseudoephedrine, epinephrine), alcohol, or any NG11-2 excipient; 9. Receiving monoamine oxidase (MAO) inhibitors or antidepressants (triptyline or imipramine types); Use of MAO inhibitor in the 14 days prior to treatment, such as isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, or tranylcypromine; 10. History or current evidence of clinically significant laboratory abnormality or any disease condition that might confound the results of the study, or interfere with the patient’s participation for the full duration of the study 11. Current participation in any other oral mucositis studies or completion/ withdrawal from any other oral mucositis studies within the last 3 months 12. Patient is, at the time of signing informed consent, a regular user of any illicit drugs, which would interfere with cooperation with the requirements of the trial; 13. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study; 14. Any other condition which, in the opinion of the Investigator, means that the patient is not a good candidate for study enrolment |
| Date of first enrolment | 01/05/2023 |
| Date of final enrolment | 30/06/2024 |
Locations
Countries of recruitment
- England
- Northern Ireland
- Scotland
- United Kingdom
Study participating centres
Great Maze Pond
London
SE1 9RT
United Kingdom
Edinburgh
Lothian
EH4 2XU
United Kingdom
Aberdeen
AB25 2ZN
United Kingdom
Edgbaston
Birmingham
B15 2TH
United Kingdom
Belfast
BT9 7AB
United Kingdom
Sponsor information
Industry
Stevenage Biocatalyst Centre
Gunnels Wood Rd
Stevenage
SG1 2FX
England
United Kingdom
| Phone | +44 1438 300880 |
|---|---|
| gary.bower@vasodynamics.co.uk |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 28/02/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | Peer reviewed scientific journals Internal report Conference presentation Publication on website Other publication Submission to regulatory authorities The study database will not be shared outside of the Sponsor group. The overall study results will be disseminated on publicly available websites |
| IPD sharing plan | Datasets are not expected to be made available due to Sponsor commercial confidentiality and the early phase nature of the study. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | version 1.2 | 12/05/2023 | No | Yes | |
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | version 2.0 | 20/12/2023 | No | Yes | |
| Results article | 11/03/2025 | Yes | No |
Additional files
Editorial Notes
11/03/2025: The basic results have been uploaded as an additional file.
30/12/2024: The intention to publish date was changed from 31/12/2024 to 28/02/2025.
04/10/2024: The overall study end date was changed from 30/09/2024 to 20/08/2024. Total final enrolment added.
20/12/2023: The following changes were made to the study record:
1. Participant information sheet uploaded.
2. The recruitment end date was changed from 31/12/2023 to 30/06/2024.
3. The overall study end date was changed from 31/01/2024 to 30/09/2024.
4. Ipswich Hospital was removed from the study participating centres.
12/05/2023: The recruitment end date was changed from 30/11/2023 to 31/12/2023. Participant information sheet uploaded.
17/04/2023: The following changes have been made:
1. The recruitment start date has been changed from 01/04/2023 to 01/05/2023.
2. The study website has been added.
3. The IPD sharing statement has been added.
01/03/2023: Internal review.
25/10/2022: Trial's existence confirmed by NHS HRA.
